Bone: Finding that osteoclasts repel osteoblast activity through Sema4D reveals novel target for bone-boosting therapies

Nature Reviews Rheumatology

Volumn 7, Issue 12, 2011, Pages 681-

  Leah, Emma ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLEXIN; PLEXIN B1; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SEMAPHORIN; SEMAPHORIN 4D; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

BONE MASS; BONE REMODELING; BONE STRENGTH; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; NONHUMAN; NOTE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 82955203747     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.175     Document Type: Note

References (3)

1. Original article Negishi-Koga, T. et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat. Med. doi:10.1038/nm.2489
2. Further reading Lewiecki, E. M. New targets for intervention in the treatment of postmenopausal osteoporosis Nat. Rev. Rheumatol. 7, 631-638 (2011)
3. Edwards, J. R. & Mundy, G. R. Advances in osteoclast biology: old findings and new insights from mouse models. Nat. Rev. Rheumatol. 7, 235-243 (2011)